Clinical Trial Update: A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating growth hormone in Phelan-McDermid syndrome and autism spectrum disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Phelan-mcdermid Syndrome

Drugs mentioned

• Growth Hormone (somatropin)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Phelan-McDermid Syndrome, Autism Spectrum Disorder (ASD) | Phase 2 | Status: COMPLETED